Active peptide, cosmetic containing active peptide and application
Through the active peptide extracted and purified from honeysuckle vine, the problem of insufficient antioxidant and cell proliferation activity in the prior art was solved, and a significant anti-skin aging effect was achieved, and used for the development of cosmetics and drugs.
Patent Information
- Application Number
- CN202411202914.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-29
AI Technical Summary
Existing anti-skin aging technologies are difficult to effectively antioxidant, enhance cell proliferation activity and delay skin aging, and lack safe and excellent biological activity active peptides.
Active peptide with amino acid sequence MQWNCPLGSAVITLHYRGDK was obtained by extracting and enzymatic decomposition and purification from honeysuckle vine and applied to cosmetics and drugs to enhance antioxidant, promote cell proliferation and delay skin aging.
It has achieved significant improvement of cell proliferation activity, reduced cell aging level and reactive oxygen level, and has good anti-skin aging effects, and can be used to develop anti-skin aging cosmetics and drugs.
Smart Images

Figure CN118994318A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cosmetics, and in particular to an active peptide, cosmetics containing the active peptide and applications thereof. Background Art
[0002] The skin is the largest organ in the human body and plays a variety of important functions, including protection, regulating body temperature and sensation. However, as we age, the skin undergoes a series of structural and functional changes, manifested as sagging skin, increased wrinkles, decreased elasticity, pigmentation, etc., which are typical characteristics of skin aging. Among them, skin aging is a complex biological process that is affected by both internal and external factors. Internal factors include genes, hormone levels, etc.; external factors include ultraviolet radiation, environmental pollution, lifestyle habits, etc.
[0003] At present, the research and application of anti-skin aging are mainly concentrated in the following aspects:
[0004] Antioxidant: Free radicals are one of the main causes of skin aging. Antioxidants can neutralize free radicals and slow down the skin aging process.
[0005] Promote collagen synthesis: Collagen is an important component of the skin. As we age, collagen synthesis decreases. Ingredients that promote collagen synthesis can improve skin elasticity and firmness.
[0006] Moisturizing: Keeping your skin hydrated is an important measure to prevent dry skin and wrinkle formation;
[0007] Anti-inflammatory: Inflammatory reactions accelerate skin aging, and anti-inflammatory ingredients can relieve inflammation and protect the skin;
[0008] At present, active peptides have become a hot topic in anti-aging cosmetics and drug research due to their excellent biological activity and safety. Therefore, finding active peptides that can fight skin aging has become an important direction. Summary of the invention
[0009] The purpose of the present invention is to overcome the deficiencies of the prior art and provide an active peptide, a cosmetic containing the active peptide and its application. To achieve the above purpose, the present invention provides the following technical solutions:
[0010] In a first aspect, the present invention provides an active peptide, the amino acid sequence of the active peptide is MQWNCPLGSAVITLHYRGDK.
[0011] Preferably, the present invention provides a method for preparing the above-mentioned active peptide as follows:
[0012] S1. Select clean honeysuckle vines, crush them into 1-2 mm using a grinder, mix the honeysuckle vine powder with 4 times the volume of ethanol, let it stand at 4°C for 12 hours, filter and discard the ethanol, and treat the powder at room temperature until it is completely dry;
[0013] S2, the first stage of enzymatic hydrolysis: the dried honeysuckle vine powder is mixed with a pH 8.0 phosphate buffer at a ratio of 1:10, and the protease Prote AX and trypsin are added, wherein the amount of the protease Prote AX and trypsin added is 1% of the weight of the honeysuckle vine powder, and the enzymatic hydrolysis is carried out in a water bath at 55° C. for 4 hours, with regular stirring to keep the mixture uniform, and then heated to 85° C. for 10 minutes to inactivate the enzyme;
[0014] S3, second stage of enzymatic hydrolysis: the pH of the enzymatic hydrolyzate was adjusted to 6.5, and grape protease was added in an amount of 0.5% of the weight of the honeysuckle vine powder, and the enzymatic hydrolysis was continued at 45°C for 2 hours, and then heated to 85°C again for 10 minutes to inactivate the enzyme;
[0015] S4. After the enzymatic hydrolysis is completed, the mixture is immediately centrifuged at 4°C and the centrifugal force is set to 10,000 g for 20 minutes to remove undissolved solids and protein precipitates, and the supernatant is treated with an ultrafiltration membrane with a molecular weight cutoff of 3 kDa to remove low molecular weight impurities and concentrate the polypeptides;
[0016] S5, pre-equilibrate the DEAE-cellulose column in 20 mM Tris-HCl buffer, pH 8.0, load the concentrated peptide sample onto the equilibrated DEAE-cellulose column, wash the column with pH 8.0, 20 mM Tris-HCl buffer, use NaCl gradient elution, the gradient range gradually increases from 0 M NaCl to 1 M NaCl, and collect the eluate;
[0017] S6. RP-HPLC purification was performed using a C18 column, with an elution procedure of 0-100% acetonitrile gradient containing 0.1% trifluoroacetic acid, a flow rate of 1 ml / min, and a detection wavelength of 220 nm to collect the target peptide peak;
[0018] S7, final purification was performed using a Sephadex G-25 gel column with a mobile phase of 0.1 M phosphate buffer, pH 7.0;
[0019] S8. Use MALDI-TOF mass spectrometry to confirm the molecular weight and purity of the polypeptide, and confirm that the sequence of the target polypeptide is MQWNCPLGSAVITLHYRGDK.
[0020] In a second aspect, the present invention provides a use of an active peptide in the preparation of anti-skin aging cosmetics, wherein the amino acid sequence of the active peptide is MQWNCPLGSAVITLHYRGDK.
[0021] Preferably, the present invention also provides a cosmetic comprising the above active peptide.
[0022] Preferably, the cosmetic is a facial cream, essence, lotion or facial mask.
[0023] In a third aspect, the present invention further provides a use of an active peptide in the preparation of an anti-skin aging drug, wherein the amino acid sequence of the active peptide is MQWNCPLGSAVITLHYRGDK.
[0024] Preferably, the medicine comprises: a therapeutically effective dose of the active peptide and pharmaceutically acceptable excipients.
[0025] The difference between the present invention and the prior art is that the present invention achieves the following technical effects:
[0026] The present invention discovers an active peptide, cosmetics containing the active peptide and applications through experiments. The polypeptide of the present application has the effects of anti-oxidation, enhancing cell proliferation activity, anti-aging and delaying skin aging, and can be used to develop and prepare cosmetics against skin aging. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 1 is the cell proliferation curve of each group in the experiment of the present invention. DETAILED DESCRIPTION
[0028] The following examples are provided to facilitate a better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.
[0029] Example 1
[0030] An embodiment of the present invention provides an active peptide, the amino acid sequence of the active peptide is MQWNCPLGSAVITLHYRGDK, and the corresponding sequence of the three-letter abbreviation is: Met-Gln-Trp-Asn-Cys-Pro-Leu-Gly-Ser-Ala-Val-Ile-Thr-Leu-His-Tyr-Arg-Gly-Asp-Lys.
[0031] Example 2
[0032] The present invention provides a method for preparing the active peptide described in Example 1, which is as follows:
[0033] S1. Select clean honeysuckle vines, crush them into 1-2 mm using a grinder, mix the honeysuckle vine powder with 4 times the volume of ethanol, let it stand at 4°C for 12 hours, filter and discard the ethanol, and treat the powder at room temperature until it is completely dry;
[0034] S2, the first stage of enzymatic hydrolysis: the dried honeysuckle vine powder is mixed with a pH 8.0 phosphate buffer at a ratio of 1:10, and the protease Prote AX and trypsin are added, wherein the amount of the protease Prote AX and trypsin added is 1% of the weight of the honeysuckle vine powder, and the enzymatic hydrolysis is carried out in a water bath at 55° C. for 4 hours, with regular stirring to keep the mixture uniform, and then heated to 85° C. for 10 minutes to inactivate the enzyme;
[0035] S3, second stage of enzymatic hydrolysis: the pH of the enzymatic hydrolyzate was adjusted to 6.5, and grape protease was added in an amount of 0.5% of the weight of the honeysuckle vine powder, and the enzymatic hydrolysis was continued at 45°C for 2 hours, and then heated to 85°C again for 10 minutes to inactivate the enzyme;
[0036] S4. After the enzymatic hydrolysis is completed, the mixture is immediately centrifuged at 4°C and the centrifugal force is set to 10,000 g for 20 minutes to remove undissolved solids and protein precipitates, and the supernatant is treated with an ultrafiltration membrane with a molecular weight cutoff of 3 kDa to remove low molecular weight impurities and concentrate the polypeptides;
[0037] S5, pre-equilibrate the DEAE-cellulose column in 20 mM Tris-HCl buffer, pH 8.0, load the concentrated peptide sample onto the equilibrated DEAE-cellulose column, wash the column with pH 8.0, 20 mM Tris-HCl buffer, use NaCl gradient elution, the gradient range gradually increases from 0 M NaCl to 1 M NaCl, and collect the eluate;
[0038] S6. RP-HPLC purification was performed using a C18 column, with an elution procedure of 0-100% acetonitrile gradient containing 0.1% trifluoroacetic acid, a flow rate of 1 ml / min, and a detection wavelength of 220 nm to collect the target peptide peak;
[0039] S7, final purification was performed using a Sephadex G-25 gel column with a mobile phase of 0.1 M phosphate buffer, pH 7.0;
[0040] S8. Use MALDI-TOF mass spectrometry to confirm the molecular weight and purity of the polypeptide, and confirm that the sequence of the target polypeptide is MQWNCPLGSAVITLHYRGDK.
[0041] Example 3
[0042] The embodiment of the present invention provides a cosmetic comprising the active peptide as described in embodiment 1.
[0043] In addition, the cosmetic is a facial cream, essence, lotion or facial mask.
[0044] Experimental Example 1
[0045] 1. Materials
[0046] The active peptide of the present application was prepared by the inventor using the method of Example 2, and the amino acid sequence is MQWNCPLGSAVITLHYRGDK;
[0047] Human dermal fibroblasts (HDFs) were purchased from ATCC;
[0048] Fetal bovine serum (FBS), DMEM high glucose medium (DMEM-HG), and DMEM low glucose medium (DMEM-LG) were purchased from HyClone;
[0049] CCK-8 kit, cell senescence β-galactosidase staining kit, and DCFH-DA reactive oxygen species (ROS) detection kit were purchased from Biotech.
[0050] 2. Methods
[0051] 1. Cell Culture and Grouping
[0052] HDFs cells were cultured in DMEM-LG medium containing 10% fetal bovine serum and 1% double antibody at 37°C, 5% CO2 and saturated humidity, and the medium was changed every 2-3 days; HDFs in the logarithmic growth phase were divided into five groups: blank group, model group, low-concentration polypeptide group, medium-concentration polypeptide group and high-concentration polypeptide group.
[0053] Among them, the blank group: cultured with low-sugar culture medium throughout the process; the model group: cultured with high-sugar culture medium, without active peptide intervention, to simulate aging cells; the low-concentration polypeptide group: high-sugar culture medium + 50μg / mL polypeptide; the medium-concentration polypeptide group: high-sugar culture medium + 100μg / mL polypeptide; the high-concentration polypeptide group: high-sugar culture medium + 200μg / mL polypeptide.
[0054] 2. Cell Proliferation Activity Detection
[0055] Use CCK-8 kit to detect cell proliferation activity:
[0056] HDFs cells in logarithmic growth phase were taken, digested with 0.25% trypsin, resuspended in DMEM-LG medium containing 10% FBS and 1% double antibody, and counted under a microscope; 5000 cells / 200 μL culture medium were inoculated in a 96-well plate per well, and grouped according to the above grouping method, with 5 replicate wells in each group; after culturing at 37°C, 5% CO2, and saturated humidity for 24 hours, the corresponding culture medium was replaced for each group; after continued culturing for 24, 48, and 72 hours, 10 μL CCK-8 solution was added to each well, incubated for 4 hours, placed in an ELISA reader, and the absorbance (OD) value was read at a wavelength of 450 nm to draw a proliferation curve.
[0057] 3. Detection of cell senescence level
[0058] Detection of cell senescence using β-galactosidase staining kit:
[0059] HDFs cells in logarithmic growth phase were obtained, digested with 0.25% trypsin, resuspended in DMEM-LG medium containing 10% FBS and 1% double antibody, and inoculated in culture flasks at a culture density of 1×10^6 cells / mL; the cells were grouped according to the above grouping method, and after 24 hours of culture, the corresponding culture medium was replaced every 48 hours for 12 days; the cells were collected, and the cell senescence level was detected using a β-galactosidase detection kit, the positively stained cells were counted under a microscope, and the senescence rate was calculated.
[0060] 4. Detection of reactive oxygen species (ROS) levels
[0061] Use DCFH-DA reactive oxygen species detection kit to detect intracellular reactive oxygen species levels:
[0062] HDFs cells in logarithmic growth phase were taken, digested with 0.25% trypsin, resuspended in DMEM-LG medium containing 10% FBS and 1% double antibody, and inoculated in culture flasks at a culture density of 1×10^6 cells / mL; grouped according to the above grouping method, and after 24 hours of culture, the corresponding culture medium of each group was replaced every 48 hours for 12 days; the cells were collected, washed three times with PBS, 10μM DCFH-DA probe was added to each well, incubated at 37℃ for 20 minutes, and after washing three times, the fluorescence images were observed and taken using a fluorescence microscope to determine the level of intracellular reactive oxygen species.
[0063] 3. Data Analysis
[0064] The data were expressed as mean ± SD, and the t test was used for comparison among the groups. P < 0.05 indicated a significant difference.
[0065] 4. Experimental Results and Analysis
[0066] 1. Cell proliferation activity
[0067] The OD values of each group are shown in Table 1. Figure 1 .
[0068] Experimental results: Compared with the blank group, the proliferation activity of HDFs cells in the model group was significantly weakened; compared with the model group, the proliferation activity of HDFs cells in the low-concentration polypeptide group, medium-concentration polypeptide group, and high-concentration polypeptide group was significantly enhanced, and the proliferation activity of HDFs cells in the high-concentration polypeptide group was the strongest.
[0069] Table 1 OD values of each group
[0070]
[0071] 2. Cellular senescence level
[0072] The positive rate of β-galactosidase staining in each group is shown in Table 2:
[0073] Experimental results: Compared with the blank group, the staining positive rate of HDFs cells in the model group was significantly increased; compared with the model group, the staining positive rate of HDFs cells in the low concentration polypeptide group, medium concentration polypeptide group, and high concentration polypeptide group was significantly decreased, and the staining positive rate of HDFs cells in the high concentration polypeptide group was the lowest.
[0074] Table 2 β-galactosidase staining positive rate in each group
[0075] Group Number of positive cells Total cell number Positive rate (%) Blank Group 23 1000 2.3 Model Group 225 1000 22.5 Low concentration peptide group 171 1000 17.1 Medium concentration peptide group 137 1000 13.7 High concentration peptide group 82 1000 8.2
[0076] 3. Reactive oxygen species (ROS) levels
[0077] The ROS levels in each group are shown in Table 3:
[0078] Experimental results: Compared with the blank group, the ROS level of HDFs cells in the model group was significantly increased; compared with the model group, the ROS levels of HDFs cells in the low-concentration polypeptide group, medium-concentration polypeptide group, and high-concentration polypeptide group were significantly decreased, and the ROS level of HDFs cells in the high-concentration polypeptide group was the lowest.
[0079] Table 3 ROS levels in each group
[0080]
[0081]
[0082] V. Conclusion
[0083] Experimental data show that the polypeptide of the present application can significantly increase the proliferation activity of HDFs cells, reduce the level of cell senescence and reactive oxygen levels, and has a good anti-skin aging effect.
[0084] Experimental Example 2
[0085] 1. Materials
[0086] The active peptide of the present application was prepared by the inventor using the method of Example 2, and the amino acid sequence is MQWNCPLGSAVITLHYRGDK;
[0087] Select Animal:
[0088] Species: C57BL / 6 mice;
[0089] Gender: male and female;
[0090] Age: 2-3 months;
[0091] Weight: 20-25g;
[0092] Adaptation period: The mice were allowed to adapt to the experimental environment for one week before the experiment to ensure that they were adapted to the environmental changes and reduce stress responses.
[0093] 2. Experimental Grouping
[0094] Randomly divided into four groups (10 mice in each group):
[0095] Control group: no peptide treatment, only conventional feeding and management;
[0096] Low-dose peptide group: 1 mg / kg of peptide was injected subcutaneously every day;
[0097] Medium-dose peptide group: 5 mg / kg of peptide was injected subcutaneously every day;
[0098] High-dose peptide group: 10 mg / kg of peptide was injected subcutaneously every day.
[0099] The corresponding dose of peptide was administered daily by subcutaneous injection for 28 consecutive days.
[0100] 3. Preparation of Skin Aging Model
[0101] UV exposure:
[0102] Except for the control group, the back skin of mice in other groups was irradiated with low-dose UVB (0.5 J / cm2 once a day). 2 ) for 5 consecutive days to induce early skin aging.
[0103] IV. Main Observation Indexes
[0104] Skin elasticity measurement:
[0105] The skin elasticity of the mouse back was measured before and after the experiment using a cutometer, and the skin elasticity coefficient (R0, unit: mm) was recorded;
[0106] Collagen Content:
[0107] The collagen content in the skin was quantified using Sirius Red staining, and the collagen content (OD value) was recorded using optical density measurement;
[0108] Antioxidant enzyme activity:
[0109] The activities of SOD (superoxide dismutase) and GPx (glutathione peroxidase) in skin tissue were measured, and the activities of SOD and GPx (U / mg protein) were recorded respectively.
[0110] V. Experimental Results
[0111] The elastic modulus R0 data measured using Cutometer are as follows:
[0112] Control group: 1.21±0.10mm;
[0113] Low-dose peptide group: 1.23±0.12mm;
[0114] Medium-dose peptide group: 1.26±0.14mm;
[0115] High-dose peptide group: 1.28±0.15mm.
[0116] The OD values after Sirius Red staining are as follows:
[0117] Control group: 0.42±0.03;
[0118] Low-dose peptide group: 0.51±0.04;
[0119] Medium-dose peptide group: 0.68±0.05;
[0120] High-dose peptide group: 0.77±0.06.
[0121] The activity data of SOD and GPx are as follows:
[0122] SOD activity:
[0123] Control group: 82±5U / mg protein;
[0124] Low-dose peptide group: 85±6U / mg protein;
[0125] Medium-dose peptide group: 89±7U / mg protein;
[0126] High-dose peptide group: 94±8U / mg protein;
[0127] GPx activity:
[0128] Control group: 52 ± 4 U / mg protein;
[0129] Low-dose peptide group: 56±5U / mg protein;
[0130] Medium-dose peptide group: 58±6U / mg protein;
[0131] High-dose peptide group: 63±7U / mg protein.
[0132] The skin elasticity of the polypeptide-treated group of the present application is significantly improved compared with that of the control group. Peptide treatment can significantly increase the collagen content in the skin. The SOD and GPx activities of the high-dose polypeptide group are significantly higher than those of the control group. Therefore, the polypeptide of the present application has a good anti-skin aging effect.
[0133] The embodiments described above are merely descriptions of preferred implementation modes of the present invention and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. An active peptide, Features: The amino acid sequence of the active peptide is MQWNCPLGSA VITLHYRGDK.
2. The active peptide according to claim 1, It is characterized in that The preparation method of the active peptide is as follows: S1. Select clean honeysuckle vines, crush them into 1-2 mm using a grinder, mix the honeysuckle vine powder with 4 times the volume of ethanol, let it stand at 4°C for 12 hours, filter and discard the ethanol, and treat the powder at room temperature until it is completely dry; S2, the first stage of enzymatic hydrolysis: the dried honeysuckle vine powder is mixed with a pH 8.0 phosphate buffer at a ratio of 1:10, and the protease Prote AX and trypsin are added, wherein the amount of the protease Prote AX and trypsin added is 1% of the weight of the honeysuckle vine powder, and the enzymatic hydrolysis is carried out in a water bath at 55° C. for 4 hours, with regular stirring to keep the mixture uniform, and then heated to 85° C. for 10 minutes to inactivate the enzyme; S3, second stage of enzymatic hydrolysis: the pH of the enzymatic hydrolyzate was adjusted to 6.5, and grape protease was added in an amount of 0.5% of the weight of the honeysuckle vine powder, and the enzymatic hydrolysis was continued at 45°C for 2 hours, and then heated to 85°C again for 10 minutes to inactivate the enzyme; S4. After the enzymatic hydrolysis is completed, the mixture is immediately centrifuged at 4°C and the centrifugal force is set to 10,000 g for 20 minutes to remove undissolved solids and protein precipitates, and the supernatant is treated with an ultrafiltration membrane with a molecular weight cutoff of 3 kDa to remove low molecular weight impurities and concentrate the polypeptides; S5, pre-equilibrate the DEAE-cellulose column in 20 mM Tris-HCl buffer, pH 8.0, load the concentrated peptide sample onto the equilibrated DEAE-cellulose column, wash the column with pH 8.0, 20 mM Tris-HCl buffer, use NaCl gradient elution, the gradient range gradually increases from 0 M NaCl to 1 M NaCl, and collect the eluate; S6. RP-HPLC purification was performed using a C18 column, with an elution procedure of 0-100% acetonitrile gradient containing 0.1% trifluoroacetic acid, a flow rate of 1 ml / min, and a detection wavelength of 220 nm to collect the target peptide peak; S7, final purification was performed using a Sephadex G-25 gel column with a mobile phase of 0.1 M phosphate buffer, pH 7.0; S8. Use MALDI-TOF mass spectrometry to confirm the molecular weight and purity of the polypeptide, and confirm that the sequence of the target polypeptide is MQWNCPLGSAVITLHYRGDK.
3. Use of an active peptide in the preparation of anti-skin aging cosmetics, wherein the amino acid sequence of the active peptide is MQWNCPLGSAVITLHYRGDK.
4. A cosmetic product, It is characterized in that The invention comprises the active peptide as claimed in claim 1.
5. The cosmetic according to claim 4, It is characterized in that The cosmetics are face cream, essence, lotion or face mask.
6. Use of an active peptide in the preparation of an anti-skin aging drug, wherein the amino acid sequence of the active peptide is MQWNCPLGSAVITLHYRGDK.
7. The use according to claim 6, It is characterized in that The medicine comprises: a therapeutically effective dose of the active peptide and pharmaceutically acceptable excipients.
Citation Information
Patent Citations
Active polypeptide, production method and application in aspect of anti-aging make-up
CN111777662A
Plant-derived polypeptide with anti-aging effect, face cream containing plant-derived polypeptide and preparation method of face cream
CN112080543A
Polypeptide for preventing ultraviolet skin injury
CN113683662A
Active peptide, anti-skin aging application and commercialized application in cosmetics
CN114381488A
Bioactive peptide and application thereof in preparation of skin wound repairing cosmetics
CN117510592A
Cited By
Skin anti-aging biological agent reset by extracellular matrix mediated dermal microenvironment
CN122427247A
